Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 proof-of-concept trial of CYR-101 in schizophrenia
2007-007538-21Phase 2Active
- Sponsor
- Minerva Therapeutics
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing CYR-101 with Placebo (2 arms). Primary endpoints: Change in PANSS total score from baseline to 1 month and Change in PANSS subscale scores from baseline to 1 month. Started Feb 2008; status: active.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2007-007538-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007538-21.